Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging.
Journal
Physics and imaging in radiation oncology
ISSN: 2405-6316
Titre abrégé: Phys Imaging Radiat Oncol
Pays: Netherlands
ID NLM: 101704276
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
received:
28
06
2024
revised:
14
08
2024
accepted:
18
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
17
9
2024
Statut:
epublish
Résumé
Dose escalation in external radiotherapy of prostate cancer shows promising results in terms of biochemical disease-free survival. Boost volume delineation guidelines are sparse which may cause high interobserver variability. The aim of this research was to characterize gross tumor volume (GTV) delineations based on multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen-positron emission tomography (PSMA-PET) in relation to histopathology-validated Gleason grade 4 and 5 regions. The study participants were examined with [ Median DSC (STAPLE) for different GTVs varied between 0.33 and 0.52. GTV The combined use of mpMRI or PSMA-PET/mpMRI shows promise, achieving higher DSC and lesion coverage while minimizing non-malignant tissue inclusion, in comparison to the use of a single image type with an added CTV margin.
Sections du résumé
Background and purpose
UNASSIGNED
Dose escalation in external radiotherapy of prostate cancer shows promising results in terms of biochemical disease-free survival. Boost volume delineation guidelines are sparse which may cause high interobserver variability. The aim of this research was to characterize gross tumor volume (GTV) delineations based on multiparametric magnetic resonance imaging (mpMRI) and prostate specific membrane antigen-positron emission tomography (PSMA-PET) in relation to histopathology-validated Gleason grade 4 and 5 regions.
Material and methods
UNASSIGNED
The study participants were examined with [
Results
UNASSIGNED
Median DSC (STAPLE) for different GTVs varied between 0.33 and 0.52. GTV
Conclusion
UNASSIGNED
The combined use of mpMRI or PSMA-PET/mpMRI shows promise, achieving higher DSC and lesion coverage while minimizing non-malignant tissue inclusion, in comparison to the use of a single image type with an added CTV margin.
Identifiants
pubmed: 39286772
doi: 10.1016/j.phro.2024.100633
pii: S2405-6316(24)00103-9
pmc: PMC11402543
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100633Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
This work was funded by Swedish Cancer Society, Cancer research foundation of Northen Sweden, Prostatacancerförbundet and Västerbotten County. Furthermore, Joakim Jonsson and Tufve Nyholm are part-owner in Hero Imaging AB which produces the software HERO that were used in the analysis.
Références
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1056-63
pubmed: 21147514
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):682-9
pubmed: 17398026
Phys Imaging Radiat Oncol. 2021 Apr 12;18:19-25
pubmed: 34258403
BJU Int. 2014 Dec;114(6b):E105-E112
pubmed: 24673731
J Urol. 2021 Feb;205(2):444-451
pubmed: 33026934
Radiat Oncol. 2013 May 24;8:126
pubmed: 23706145
J Urol. 2017 Feb;197(2):320-326
pubmed: 27484386
Chin J Cancer Res. 2016 Feb;28(1):58-64
pubmed: 27041927
Eur Urol. 2011 Dec;60(6):1133-9
pubmed: 21889832
Insights Imaging. 2018 Feb;9(1):87-101
pubmed: 29063480
Radiother Oncol. 2019 Dec;141:208-213
pubmed: 31431386
Radiother Oncol. 2019 Dec;141:214-219
pubmed: 31431366
Cancer Imaging. 2022 Jul 22;22(1):36
pubmed: 35869521
Int J Radiat Oncol Biol Phys. 2024 Jan 1;118(1):66-73
pubmed: 37725026
Eur Urol. 2022 Sep;82(3):252-257
pubmed: 34953603
J Nucl Med. 2022 Jun;63(6):847-854
pubmed: 34649942
IEEE Trans Med Imaging. 2004 Jul;23(7):903-21
pubmed: 15250643
Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1145-1152
pubmed: 37453559
Commun Med (Lond). 2023 Nov 9;3(1):164
pubmed: 37945817
JAMA Oncol. 2018 Jun 14;4(6):e180039
pubmed: 29543933
Radiother Oncol. 2018 Aug;128(2):321-326
pubmed: 29731160
Nucl Med Commun. 2023 Nov 1;44(11):997-1004
pubmed: 37615497
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2796-2803
pubmed: 32342192
Front Oncol. 2020 Nov 23;10:596756
pubmed: 33330088
Insights Imaging. 2023 Jun 7;14(1):105
pubmed: 37286770
J Clin Oncol. 2021 Mar 1;39(7):787-796
pubmed: 33471548